Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 15/20 | 0.68 |
| ▸ | F10 | P00742 | 8/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13709677 | 0.83 | F9 (0.72) | F9F10 | |
| SCHEMBL13709656 | 0.81 | F9 (1.00) | F9F10NPC1RAB9AMAPT | |
| SCHEMBL13709747 | 0.81 | F9 (0.62) | F9F10 | |
| SCHEMBL13709742 | 0.80 | F9 (0.71) | F9F10 | |
| SCHEMBL13709689 | 0.78 | F9 (0.58) | F9F10 | |
| SCHEMBL13709704 | 0.77 | F9 (0.60) | F9F10 | |
| SCHEMBL13709710 | 0.77 | F9 (0.70) | F9F10 | |
| SCHEMBL13709643 | 0.77 | F9 (0.66) | F9F10NPC1RAB9AMAPT | |
| SCHEMBL13709748 | 0.75 | F9 (0.53) | F9F10 | |
| SCHEMBL13709679 | 0.75 | F9 (0.53) | F9F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | TRIGEN LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | TRIGEN LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | F12, F5, F3 | F9 5/4885F10 7/4885NPC1 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.